OBI Pharma, Inc., a Taiwan biotech developing therapeutic agents and next-gen active immunotherapies for a range of unmet medical needs and indications, is scheduled to host an industry-sponsored satellite symposium at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting taking place in Copenhagen, Denmark, next month.
The symposium, titled “Novel Approaches to Active Immunotherapy in Oncology – Targeting Globo Series with Adagloxad Simolenin,” will review data on targeting Globo Series antigens in metastatic breast cancer and other cancers with OBI Pharma’s investigational active immunotherapy, Adagloxad Simolenin (formerly OBI-822), and will examine the future of active immunotherapy in oncology. Notably, Adagloxad Simolenin incorporates Stellar KLH™, an immune-stimulating carrier molecule manufactured by Stellar Biotechnologies, Inc. (NASDAQ: SBOT).
“OBI Pharma is pleased to host this educational symposium at the prestigious ESMO meeting to discuss the future of active immunotherapy in oncology and the role of Adagloxad Simolenin, a novel first-in-class active immunotherapy,” said Amy Huang, general manager of OBI Pharma. “OBI is committed to continuing the development of Adagloxad Simolenin for patients with metastatic breast cancer and other cancers.”
This year’s ESMO meeting will take place October 7-11, 2016. OBI Pharma will make its presentation on October 10 from 6:30-8 p.m. CEST in the Athens Auditorium at the Bella Center in Copenhagen.
The symposium will be moderated by Stephen Johnston, MA, PhD, FRCP, professor of Breast Cancer Medicine and Medical Oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London.
Other presenters will include:
- Chiun-Sheng Huang, MD, professor of surgery and director of The Breast Center at the National Taiwan University Hospital and the National Taiwan University College of Medicine
- Heather L. McArthur, MD, MPH, medical oncologist at Memorial Sloan Kettering Cancer Center
- Chi-Huey Wong, PhD, professor of chemistry at The Scripps Research Institute, Past President Academia Sinica
The symposium is open to all ESMO attendees. Pre-registration is required online at http://activeimmunotherapy.apothecom.com. Dinner will be included.
For more information, visit www.obipharma.com/en
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing network of more than 5,000 key distribution outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, visit www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.net
